Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
BEAT AML
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we report initial findings from the Beat AML programme on a cohort of 672 tumour specimens collected from 562 patients. We assessed these specimens using whole-exome sequencing, RNA sequencing and analyses of ex vivo drug sensitivity. Our data reveal mutational events that have not previously been detected in AML. We show that the response to drugs is associated with mutational status, including instances of drug sensitivity that are specific to combinatorial mutational events. Integration with RNA sequencing also revealed gene expression signatures, which predict a role for specific gene networks in the drug response. Collectively, we have generated a dataset - accessible through the Beat AML data viewer (Vizome) - that can be leveraged to address clinical, genomic, transcriptomic and functional analyses of the biology of AML. The dataset presented in CCDC only includes pediatric and young adult cases.
BEAT AML 2.0
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large cohort of AML patients, which facilitated discovery of functional genomic correlates. Here, we present a dataset that has been harmonized with our initial report to yield a cumulative cohort of 805 patients (942 specimens). We show strong cross-cohort concordance and identify features of drug response. Further, deconvoluting transcriptomic data shows that drug sensitivity is governed broadly by AML cell differentiation state, sometimes conditionally affecting other correlates of response. Finally, modeling of clinical outcome reveals a single gene, PEAR1, to be among the strongest predictors of patient survival, especially for young patients. Collectively, this report expands a large functional genomic resource, offers avenues for mechanistic exploration and drug development, and reveals tools for predicting outcome in AML. The dataset presented in CCDC only includes pediatric and young adult cases.
Analysis of Somatic Mutations in Pediatric AML FAB-M7 Subtype by Whole Transcriptome Sequencing
To define the mutation spectrum in non-Down syndrome acute megakaryoblastic leukemia (non-DS-AMKL), we performed transcriptome sequencing on diagnostic blasts from 14 pediatric patients and validated our findings in a recurrency/validation cohort consisting of 34 pediatric and 28 adult AMKL samples. Our analysis identified a cryptic chromosome 16 inversion (inv(16)(p13.3q24.3)) in 27% of pediatric cases, which encodes a CBFA2T3-GLIS2 fusion protein. Expression of CBFA2T3-GLIS2 in Drosophila and murine hematopoietic cells induced bone morphogenic protein (BMP) signaling and resulted in a marked increase in the self-renewal capacity of hematopoietic progenitors. These data suggest that expression of CBFA2T3-GLIS2 directly contributes to leukemogenesis.
Gene Expression-Based High Throughput Screening: Primary Patient AML Blasts, Normal Neutrophils, and Normal Monocytes
GEO Series GSE983. Homo sapiens. 9 samples. Type: Expression profiling by array.
Genome wide CRISPR screen in AML chemotherapy resistance.
GEO Series GSE235688. Homo sapiens. 4 samples. Type: Other.
PHF6 suppresses self-renewal of leukemic stem cells in AML
GEO Series GSE270756. Homo sapiens; Mus musculus. 30 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Gene expression profiling of the MLL-AF9 induced AML cells (wild type and Dnmt3b-KO)
GEO Series GSE75401. Mus musculus. 6 samples. Type: Expression profiling by array.
Gene expression profiling of CD34+/CD38- stem cells and CD34+/CD38+ progenitor cells from healthy control samples versus acute myeloid leukemia (AML) and chronic myeloid leukemia (CML)
GEO Series GSE138883. Homo sapiens. 18 samples. Type: Expression profiling by array.
Identification of the Global miR-130a Targetome Reveals a Novel Role for TBL1XR1 in Hematopoietic Stem Cell Self-Renewal and t(8;21) AML [TBL1XR1 KD]
GEO Series GSE181139. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Depletion of the Chromatin Remodeler CHD4 Sensitizes AML Blasts to Genotoxic Agents and Reduces Tumor Formation
GEO Series GSE71865. Homo sapiens. 12 samples. Type: Expression profiling by array.
RNAseqencing of wild type (WT) and Ripk3-/- (KO) AML-12 cells in the presence (PA) of absence (C) of 125 µM palmitate-bovine serum albumin for 24 h
GEO Series GSE199155. Mus musculus. 20 samples. Type: Expression profiling by high throughput sequencing.
The genome wide mapping of H3K4kme3, H3K27ac and H3K27me3 in Ctcf f/f and Ctcf Δ/Δ CALM-AF10 AML cells [ChiP-seq]
GEO Series GSE281043. Mus musculus. 16 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
CyTOF and flow cytometry fcs files from BMMCs of patients with myeloid neoplasms (AML, MDS, CMML)
<p>This dataset contains all the flow cytometry and mass cytometry (CyTOF - CD45+ immune cells) fcs files , associated with Tasis <em>et al</em>. Preprint doi: https://doi.org/10.1101/2023.12.30.23300608</p> <p> </p>
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
ClinicalTrials.gov study NCT06561152. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
ClinicalTrials.gov study NCT07157514. IPD Sharing: Not stated. Countries: 0. Publications: 0.
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT03114228. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.
ClinicalTrials.gov study NCT03902769. IPD Sharing: NO. Countries: 0. Publications: 0.
Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)
ClinicalTrials.gov study NCT02662933. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy
ClinicalTrials.gov study NCT02303782. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS
ClinicalTrials.gov study NCT04743115. IPD Sharing: NO. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.